首页 > 最新文献

Clinical Liver Disease最新文献

英文 中文
A review of drug-induced liver injury with rash, eosinophilia, and systemic symptoms (DRESS) syndrome: Cutaneous manifestations, clinical features, and management. 药物性肝损伤伴皮疹、嗜酸性粒细胞增多和全身症状(DRESS)综合征综述:皮肤表现、临床特征和处理方法。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000198
Nitin Arora, Naga Chalasani, Sahand Rahnama-Moghadam
{"title":"A review of drug-induced liver injury with rash, eosinophilia, and systemic symptoms (DRESS) syndrome: Cutaneous manifestations, clinical features, and management.","authors":"Nitin Arora, Naga Chalasani, Sahand Rahnama-Moghadam","doi":"10.1097/CLD.0000000000000198","DOIUrl":"10.1097/CLD.0000000000000198","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic challenges in drug-induced liver injury. 药物性肝损伤的诊断难题。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000206
Paul H Hayashi, Jay H Hoofnagle
{"title":"Diagnostic challenges in drug-induced liver injury.","authors":"Paul H Hayashi, Jay H Hoofnagle","doi":"10.1097/CLD.0000000000000206","DOIUrl":"10.1097/CLD.0000000000000206","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of opioid use disorder in patients with liver disease. 肝病患者阿片类药物使用障碍的治疗。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000207
Jordana Laks, Daniel P Alford
{"title":"Treatment of opioid use disorder in patients with liver disease.","authors":"Jordana Laks, Daniel P Alford","doi":"10.1097/CLD.0000000000000207","DOIUrl":"10.1097/CLD.0000000000000207","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. 代谢功能障碍相关的脂肪肝和心血管疾病。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000181
Tooba Laeeq, Kyaw Min Tun
{"title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease.","authors":"Tooba Laeeq, Kyaw Min Tun","doi":"10.1097/CLD.0000000000000181","DOIUrl":"10.1097/CLD.0000000000000181","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to longitudinal follow-up for hepatitis B treatment in rural Sierra Leone: A mixed methods study of retention in care. 塞拉利昂农村地区乙肝治疗纵向随访的障碍:关于继续接受治疗的混合方法研究。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000225
Williams Lebbie, Lao-Tzu Allan-Blitz, Emmanuel T Nyama, Mohamed Swaray, Daniel Lavalie, Michael Mhango, Marta Patiño Rodriguez, Neil Gupta, Remy Bitwayiki

HBV disproportionately affects resource-limited settings, and retaining patients in longitudinal care remains challenging. We conducted a mixed methods investigation to understand the causes of losses to follow-up within an HBV clinic in rural Sierra Leone. We developed a multivariable logistic regression model of baseline clinical and sociodemographic factors predicting losses to follow-up, defined as failing to present for a follow-up visit within 14 months of enrollment. We included patients enrolled between April 30, 2019 and March 1, 2020, permitting 14 months of follow-up by April 30, 2021. We then developed a survey to solicit patient perspectives on the challenges surrounding retention. We interviewed randomly selected patients absent from HBV care for at least 6 months. Among 271 patients enrolled in the Kono HBV clinic, 176 (64.9%) did not have a follow-up visit within 14 months of the study end point. Incomplete baseline workup (aOR 2.9; 95% CI: 1.6-4.8), lack of treatment at baseline (aOR 5.0; 95% CI: 1.7-14.4), and having cirrhosis at baseline (aOR 3.3; 95% CI: 0.99-10.8) were independently associated with being lost to follow-up. For the patient survey, 21 patients completed the interview (median age 34 years [IQR: 25-38]). Travel-related factors were the most frequently reported barrier to retention (57%). Almost 30% suggested improved customer care might support retention in care; 24% requested to be given medication. In our setting, factors that might reduce losses to follow-up included expanded criteria for treatment initiation, overcoming transportation barriers, reducing wait times, ensuring against stockouts, and scaling up point-of-care testing services.

在资源有限的环境中,HBV 的影响尤为严重,让患者继续接受纵向治疗仍是一项挑战。我们采用混合方法进行了一项调查,以了解塞拉利昂农村地区一家 HBV 诊所中失去随访机会的原因。我们建立了一个多变量逻辑回归模型,对预测随访损失的基线临床和社会人口学因素进行了分析,随访损失的定义是在入院后 14 个月内未能进行随访。我们纳入了 2019 年 4 月 30 日至 2020 年 3 月 1 日期间入组的患者,允许在 2021 年 4 月 30 日之前进行 14 个月的随访。然后,我们制定了一项调查,以征求患者对留住患者所面临挑战的看法。我们随机采访了至少 6 个月未接受 HBV 治疗的患者。在科诺 HBV 诊所登记的 271 名患者中,有 176 人(64.9%)在研究终点后的 14 个月内没有接受随访。基线检查不完整(aOR 2.9;95% CI:1.6-4.8)、基线时缺乏治疗(aOR 5.0;95% CI:1.7-14.4)和基线时患有肝硬化(aOR 3.3;95% CI:0.99-10.8)与随访缺失独立相关。在患者调查方面,21 名患者完成了访谈(中位年龄为 34 岁 [IQR:25-38])。与旅行相关的因素是最常被报告的影响患者继续就医的障碍(57%)。近 30% 的患者认为,改善客户服务可能有助于留住患者;24% 的患者要求获得药物治疗。在我们的环境中,可减少随访损失的因素包括:扩大治疗启动标准、克服交通障碍、减少等待时间、确保无库存以及扩大护理点检测服务。
{"title":"Barriers to longitudinal follow-up for hepatitis B treatment in rural Sierra Leone: A mixed methods study of retention in care.","authors":"Williams Lebbie, Lao-Tzu Allan-Blitz, Emmanuel T Nyama, Mohamed Swaray, Daniel Lavalie, Michael Mhango, Marta Patiño Rodriguez, Neil Gupta, Remy Bitwayiki","doi":"10.1097/CLD.0000000000000225","DOIUrl":"10.1097/CLD.0000000000000225","url":null,"abstract":"<p><p>HBV disproportionately affects resource-limited settings, and retaining patients in longitudinal care remains challenging. We conducted a mixed methods investigation to understand the causes of losses to follow-up within an HBV clinic in rural Sierra Leone. We developed a multivariable logistic regression model of baseline clinical and sociodemographic factors predicting losses to follow-up, defined as failing to present for a follow-up visit within 14 months of enrollment. We included patients enrolled between April 30, 2019 and March 1, 2020, permitting 14 months of follow-up by April 30, 2021. We then developed a survey to solicit patient perspectives on the challenges surrounding retention. We interviewed randomly selected patients absent from HBV care for at least 6 months. Among 271 patients enrolled in the Kono HBV clinic, 176 (64.9%) did not have a follow-up visit within 14 months of the study end point. Incomplete baseline workup (aOR 2.9; 95% CI: 1.6-4.8), lack of treatment at baseline (aOR 5.0; 95% CI: 1.7-14.4), and having cirrhosis at baseline (aOR 3.3; 95% CI: 0.99-10.8) were independently associated with being lost to follow-up. For the patient survey, 21 patients completed the interview (median age 34 years [IQR: 25-38]). Travel-related factors were the most frequently reported barrier to retention (57%). Almost 30% suggested improved customer care might support retention in care; 24% requested to be given medication. In our setting, factors that might reduce losses to follow-up included expanded criteria for treatment initiation, overcoming transportation barriers, reducing wait times, ensuring against stockouts, and scaling up point-of-care testing services.</p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding fatigue and pruritus in primary biliary cholangitis. 了解原发性胆汁性胆管炎的疲劳和瘙痒。
Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000216
Asma Faisal
{"title":"Understanding fatigue and pruritus in primary biliary cholangitis.","authors":"Asma Faisal","doi":"10.1097/CLD.0000000000000216","DOIUrl":"10.1097/CLD.0000000000000216","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients treated with immune checkpoint inhibitors for HCC should be considered for liver transplantation. 接受免疫检查点抑制剂治疗的 HCC 患者应考虑接受肝移植。
Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000107
Media N Ismael, Calvin Kiani, Virginia Clark

{"title":"Patients treated with immune checkpoint inhibitors for HCC should be considered for liver transplantation.","authors":"Media N Ismael, Calvin Kiani, Virginia Clark","doi":"10.1097/CLD.0000000000000107","DOIUrl":"10.1097/CLD.0000000000000107","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of HBV reactivation: Challenges and opportunities. HBV 再激活的管理:挑战与机遇。
Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000143
Catherine Mezzacappa, Joseph K Lim

{"title":"Management of HBV reactivation: Challenges and opportunities.","authors":"Catherine Mezzacappa, Joseph K Lim","doi":"10.1097/CLD.0000000000000143","DOIUrl":"10.1097/CLD.0000000000000143","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reasonable expansion of surgical candidates for HCC treatment. 合理扩大 HCC 治疗手术候选者的范围。
Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000153
Samuel D Butensky, Kevin G Billingsley, Sajid A Khan

{"title":"Reasonable expansion of surgical candidates for HCC treatment.","authors":"Samuel D Butensky, Kevin G Billingsley, Sajid A Khan","doi":"10.1097/CLD.0000000000000153","DOIUrl":"10.1097/CLD.0000000000000153","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant. 接受免疫检查点抑制剂治疗的 HCC 患者不应考虑进行肝移植。
Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000108
Frances Lee, Ann Robinson, Edward Will Holt, R Todd Frederick

{"title":"Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant.","authors":"Frances Lee, Ann Robinson, Edward Will Holt, R Todd Frederick","doi":"10.1097/CLD.0000000000000108","DOIUrl":"10.1097/CLD.0000000000000108","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Liver Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1